G. Veyrac

812 total citations
41 papers, 531 citations indexed

About

G. Veyrac is a scholar working on Pharmacology, Toxicology and Pediatrics, Perinatology and Child Health. According to data from OpenAlex, G. Veyrac has authored 41 papers receiving a total of 531 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Pharmacology, 11 papers in Toxicology and 6 papers in Pediatrics, Perinatology and Child Health. Recurrent topics in G. Veyrac's work include Pharmacovigilance and Adverse Drug Reactions (11 papers), Drug-Induced Adverse Reactions (10 papers) and Pharmaceutical studies and practices (4 papers). G. Veyrac is often cited by papers focused on Pharmacovigilance and Adverse Drug Reactions (11 papers), Drug-Induced Adverse Reactions (10 papers) and Pharmaceutical studies and practices (4 papers). G. Veyrac collaborates with scholars based in France and Belgium. G. Veyrac's co-authors include Pascale Jolliet, Caroline Victorri‐Vigneau, Éric Dailly, B. Milpied, A. Soria, C. Bernier, A. Barbaud, Étienne Puymirat, Marie Bourin and Pascal Demoly and has published in prestigious journals such as Journal of the American Academy of Dermatology, Journal of Antimicrobial Chemotherapy and British Journal of Clinical Pharmacology.

In The Last Decade

G. Veyrac

36 papers receiving 521 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
G. Veyrac France 11 198 82 77 74 67 41 531
Céline Villier France 13 99 0.5× 53 0.6× 8 0.1× 51 0.7× 57 0.9× 25 547
Tzu‐Ting Chen Taiwan 16 44 0.2× 30 0.4× 63 0.8× 9 0.1× 170 2.5× 44 602
Pat Tennis United States 6 210 1.1× 56 0.7× 9 0.1× 39 0.5× 157 2.3× 6 483
Frank Rouby France 11 89 0.4× 10 0.1× 66 0.9× 14 0.2× 56 0.8× 21 528
A Venuti Italy 18 392 2.0× 110 1.3× 7 0.1× 291 3.9× 8 0.1× 56 868
Palika Datta United States 11 85 0.4× 16 0.2× 14 0.2× 8 0.1× 32 0.5× 37 600
Kristin G. Sweeney United States 5 82 0.4× 33 0.4× 4 0.1× 45 0.6× 14 0.2× 8 698
Jin Gyu Jung South Korea 14 29 0.1× 87 1.1× 32 0.4× 5 0.1× 24 0.4× 45 612
Deepak Khandelwal India 14 31 0.2× 13 0.2× 57 0.7× 8 0.1× 21 0.3× 67 868
Grigorios Trypsianis Greece 15 30 0.2× 7 0.1× 20 0.3× 19 0.3× 63 0.9× 72 834

Countries citing papers authored by G. Veyrac

Since Specialization
Citations

This map shows the geographic impact of G. Veyrac's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by G. Veyrac with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites G. Veyrac more than expected).

Fields of papers citing papers by G. Veyrac

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by G. Veyrac. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by G. Veyrac. The network helps show where G. Veyrac may publish in the future.

Co-authorship network of co-authors of G. Veyrac

This figure shows the co-authorship network connecting the top 25 collaborators of G. Veyrac. A scholar is included among the top collaborators of G. Veyrac based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with G. Veyrac. G. Veyrac is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Laforgue, Edouard‐Jules, et al.. (2025). Drugs associated with behavioral addictions: Real world analysis using the WHO pharmacovigilance database. Therapies. 1 indexed citations
2.
Selle, Frédèric, Emmanuel Seront, Rosa Conforti, et al.. (2024). Clinical and radiological pattern of olaparib-induced interstitial lung disease. BMC Pulmonary Medicine. 24(1). 448–448.
3.
Veyrac, G., et al.. (2024). Immediate allergies to chlorhexidine: A series of pediatric cases from the French pharmacovigilance database. Archives de Pédiatrie. 31(7). 419–425.
4.
Veyrac, G., et al.. (2022). Safety profile of the lopinavir/ritonavir combination before and during the SARS-CoV-2 pandemic. Therapies. 78(4). 419–425. 6 indexed citations
5.
Gouverneur, Amandine, Paola Sanchez-Peña, G. Veyrac, et al.. (2021). Neurocognitive Disorders Associated with PCSK9 Inhibitors: a Pharmacovigilance Disproportionality Analysis. Cardiovascular Drugs and Therapy. 37(2). 271–276. 7 indexed citations
6.
Soria, A., C. Bernier, G. Veyrac, et al.. (2019). Drug reaction with eosinophilia and systemic symptoms may occur within 2 weeks of drug exposure: A retrospective study. Journal of the American Academy of Dermatology. 82(3). 606–611. 55 indexed citations
7.
Duval, Xavier, Sarah Tubiana, P Giraud, et al.. (2019). Antibiotic prophylaxis for the prevention of infective endocarditis for dental procedures is not associated with fatal adverse drug reactions in France. Medicina oral, patología oral y cirugía bucal. 24(3). e296–e304. 9 indexed citations
8.
Baron, Aurélie, et al.. (2018). Immediate-Type Hypersensitivity Cross-Reactions to Proton Pump Inhibitors: A Descriptive Study of Data from the French National Pharmacovigilance Database. International Archives of Allergy and Immunology. 178(2). 159–166. 10 indexed citations
9.
Victorri‐Vigneau, Caroline, et al.. (2017). Pratiques d’utilisation du MEOPA dans un CHU : quelle conformité ?. Therapies. 72(6). 659–663. 1 indexed citations
10.
Veyrac, G., et al.. (2017). Pristinamycin-induced arthralgia and myalgia: Analysis of the French Pharmacovigilance Database. Médecine et Maladies Infectieuses. 48(1). 58–62. 2 indexed citations
11.
Guen, Christèle Gras‐Le, et al.. (2015). Adverse Drug Reactions in Pediatric Emergency Medicine. Annals of Pharmacotherapy. 49(12). 1298–1304. 10 indexed citations
12.
Moulis, Guillaume, Haleh Bagheri, L. Sailler, et al.. (2014). Are adverse drug reaction patterns different between romiplostim and eltrombopag? 2009–2013 French PharmacoVigilance assessment. European Journal of Internal Medicine. 25(8). 777–780. 23 indexed citations
13.
Veyrac, G., et al.. (2014). The Special Case of Diclofenac. 1(3). 2 indexed citations
14.
Victorri‐Vigneau, Caroline, Éric Dailly, G. Veyrac, & Pascale Jolliet. (2007). Evidence of zolpidem abuse and dependence: results of the French Centre for Evaluation and Information on Pharmacodependence (CEIP) network survey. British Journal of Clinical Pharmacology. 64(2). 198–209. 159 indexed citations
15.
Veyrac, G., L. Cellerin, & Pascale Jolliet. (2006). Un cas de pneumopathie interstitielle rapporté sous atorvastatine (Tahor®) : synthèse des cas publiés sous statines. Therapies. 61(1). 57–67. 8 indexed citations
16.
Veyrac, G., et al.. (2002). [Characteristics of hypersensitivity syndrome to lamotrigine: review of one case reported in the Regional Center of Pharmacovigilance of Nantes].. PubMed. 57(3). 289–96. 14 indexed citations
17.
Veyrac, G., et al.. (2002). [Results of a French nationwide survey of cutaneous side effects of ketoprofen gel reported between September 1996 and August 2000].. PubMed. 57(1). 55–64. 14 indexed citations
18.
Veyrac, G., et al.. (2001). [Arthralgia associated with mirtazapine].. PubMed. 55(5). 652–5. 1 indexed citations
19.
Jolliet, Pascale, G. Veyrac, & Michel Bourin. (2001). First report of mirtazapine-induced arthralgia. European Psychiatry. 16(8). 503–505. 6 indexed citations
20.
Veyrac, G., Anne Chiffoleau, L. Cellerin, C Larousse, & Michel Bourin. (2000). [Latanoprost (Xalatan) and a systemic respiratory effect? Apropos of a case].. PubMed. 54(4). 494–6. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Céline Villier Breakdown of academic impact, for papers by Tzu‐Ting Chen Breakdown of academic impact, for papers by Pat Tennis Breakdown of academic impact, for papers by Frank Rouby Breakdown of academic impact, for papers by A Venuti Breakdown of academic impact, for papers by Palika Datta Breakdown of academic impact, for papers by Kristin G. Sweeney Breakdown of academic impact, for papers by Jin Gyu Jung Breakdown of academic impact, for papers by Deepak Khandelwal Breakdown of academic impact, for papers by Grigorios Trypsianis
Rankless by CCL
2026